Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award
Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award


Agilent Technologies Inc. (NYSE: A) today announced that the Agilent Vaya Raman raw material identity verification system has received a 2020 R&D 100 Award in the Analytical/Test category. The

 
BOIRON : Projected timetable of the next publications and events 2021
BOIRON : Projected timetable of the next publications and events 2021

The projected timetable of the next publications and events for the year 2021 is the following one:

Publications Date of publication (after market closing) Information meetings
Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB

Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA
Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA


Regulatory News:



Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that a patient has passed away

Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced four poster

EOS imaging Reports 9-month Revenue up +32% Year-on-year
EOS imaging Reports 9-month Revenue up +32% Year-on-year


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Humana Announces Major Tennessee Expansion, Will Sell Medicare Advantage Plans in 31 More Counties: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Announces Major Tennessee Expansion, Will Sell Medicare Advantage Plans in 31 More Counties


As part of Humana Inc.’s (NYSE: HUM) major Tennessee expansion in 2021, the leading health and well-being company announced today it is introducing a new Medicare Advantage Health Maintenance

Waters ACQUITY PREMIER Columns Set a New Standard of Performance for Chromatographic Analyses
Waters ACQUITY PREMIER Columns Set a New Standard of Performance for Chromatographic Analyses


Waters Corporation (NYSE:WAT) today introduced ACQUITY™ PREMIER Columns, a new family of premium sub-2-micron columns featuring MaxPeak™ High Performance Surface (HPS) technology. The columns are

Agilent Early Career Professor Award Presented to Carl DeSelm
Agilent Early Career Professor Award Presented to Carl DeSelm


Agilent Technologies Inc. (NYSE: A) today announced that Carl DeSelm, M.D., Ph.D., has received the 2020 Agilent Early Career Professor Award. Dr. DeSelm is an assistant professor of Radiation

Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com
Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaign for

NanoString Technologies Announces Closing of Public Offering of $230.0 Million of Common Stock Including Exercise in Full of Option to Purchase Additional Shares: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Technologies Announces Closing of Public Offering of $230.0 Million of Common Stock Including Exercise in Full of Option to Purchase Additional Shares


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the closing of its previously announced underwritten

Premier, Inc. to Report Fiscal 2021 First-Quarter Results and Host Conference Call on November 2, 2020: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2021 First-Quarter Results and Host Conference Call on November 2, 2020


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2021 first quarter on Monday, November 2, 2020, at approximately 4:15 p.m. ET. The company will

Humana Welcomes Additional Retail Pharmacies to Preferred Medicare Part D Network: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Welcomes Additional Retail Pharmacies to Preferred Medicare Part D Network


Humana Inc. (NYSE: HUM), a leading health and well-being company, has announced that Kroger Health and its family of pharmacies, Costco, Publix and HEB have joined its preferred stand-alone

Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that

Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA


Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced

Dexcom Appoints Kyle Malady to Board of Directors: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Appoints Kyle Malady to Board of Directors


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Kyle Malady to its Board of Directors, effective immediately.



Mr

Dexcom Appoints Kyle Malady to Board of Directors: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Appoints Kyle Malady to Board of Directors


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Kyle Malady to its Board of Directors, effective immediately.



Mr

LivaNova präsentiert auf der Jahrestagung der European Association for Cardio-Thoracic Surgery neue Daten zur Demonstration der Vorteile der nahtlosen Percevalklappe: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova präsentiert auf der Jahrestagung der European Association for Cardio-Thoracic Surgery neue Daten zur Demonstration der Vorteile der nahtlosen Percevalklappe


LivaNova PLC (NASDAQ:LIVN), ein marktführendes Medizintechnik- und Innovationsunternehmen, gab heute neue Daten aus der klinischen Studie über Perceval®, dem nahtlosen Implantat im Vergleich zum

Evotec: Jetzt ist auch Abu Dhabi an Bord
Evotec: Jetzt ist auch Abu Dhabi an Bord

Wie das Hamburger Biotechnologieunternehmen Evotec (WKN: 566480) heute früh vermeldete, investieren die Mubadala Investment Company sowie die Novo Holdings 250 Millionen Euro im Rahmen einer

NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today

EOS imaging: First EOSedge™ Installation in Australia
EOS imaging: First EOSedge™ Installation in Australia


EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, announces the

LivaNova Confirms Receipt of Letter from PrimeStone Capital: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Confirms Receipt of Letter from PrimeStone Capital


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today confirmed receipt of a letter from PrimeStone Capital LLP (PrimeStone) to its Board of Directors and

EOS imaging: First EOSedgeTM Installation in Australia
EOS imaging: First EOSedgeTM Installation in Australia


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Humana, Humana Foundation Commit More Than $1 Million to COVID-19 Relief and Recovery Efforts in Georgia: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana, Humana Foundation Commit More Than $1 Million to COVID-19 Relief and Recovery Efforts in Georgia


Together, Humana Inc. (NYSE: HUM) and the company’s philanthropic arm, The Humana Foundation, have committed more than $1 million in COVID-19 relief for communities in Georgia to date.



“The